ArticleClinical rheumatology2011
Serum levels of IL-33 is increased in patients with ankylosing spondylitis.
Article in Clinical rheumatology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 48 citations in OpenAlex.
- Bone changes and curative effect of infliximab in patients with ankylosing spondylitis.Journal of musculoskeletal & neuronal interactions · 2020Trial
- Recent Updates in the Immunopathology of Type 3 Immunity-Mediated Enthesitis.Current rheumatology reports · 2021Review
- IL-33 in Rheumatic Diseases.Frontiers in medicine · 2021Review
- IL-33 promotes anemia during chronic inflammation by inhibiting differentiation of erythroid progenitors.The Journal of experimental medicine · 2020Article
- Biomarker development for axial spondyloarthritis.Nature reviews. Rheumatology · 2020Review
- GM-CSF drives dysregulated hematopoietic stem cell activity and pathogenic extramedullary myelopoiesis in experimental spondyloarthritis.Nature communications · 2020Article
- An update on serum biomarkers to assess axial spondyloarthritis and to guide treatment decision.Therapeutic advances in musculoskeletal disease · 2020Review
- Allergic inflammation is initiated by IL-33-dependent crosstalk between mast cells and basophils.PloS one · 2020Article
- Correlation of the expression of miR-146a in peripheral blood mononuclear cells of patients with ankylosing spondylitis and inflammatory factors.Experimental and therapeutic medicine · 2017Article
- Interleukin-33 in health and disease.Nature reviews. Immunology · 2016Review
- Secukinumab: a promising therapeutic option in spondyloarthritis.Clinical rheumatology · 2016Review
- Biomarkers for diagnosis, monitoring of progression, and treatment responses in ankylosing spondylitis and axial spondyloarthritis.Clinical rheumatology · 2015Review
- Increased levels of soluble ST2 in patients with active newly diagnosed ANCA-associated vasculitis.Mediators of inflammation · 2015Article
- Emerging role of interleukin-33 in autoimmune diseases.Immunology · 2014Review
- Serum level of interleukin-33 and soluble ST2 and their association with disease activity in patients with Behcet's disease.Journal of Korean medical science · 2013Article
- Frequency of fragmented QRS in ankylosing spondylitis : a prospective controlled study.Zeitschrift fur Rheumatologie · 2013Article
- The role of IL-33 in rheumatic diseases.Clinical & developmental immunology · 2013Review
- Changes in serum Interleukin-33 concentration before and after treatment with pegylated interferon alfa-2a plus ribavirin in patients with chronic hepatitis C genotype 1b infection.Hepatitis monthly · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Interleukin-33 (IL-33) is implicated in rheumatoid arthritis with effects of promoting tumor necrosis factor-alpha (TNF-α) and interleukin-17 (IL-17) productions, which have been demonstrated to play a pivotal role in ankylosing spondylitis (AS). However, changes of IL-33 levels and its effects in AS have not been investigated. Eighty-nine and 178 healthy controls were included in the current study. Erythrocyte sedimentation rate, serum levels of C-reactive protein, IL-17, and IL-33 were determined. Effects of IL-33 on TNF-α and IL-6 productions were investigated. Effects of IL-33 on neutrophil migration were also evaluated. Serum levels of IL-33 were elevated in AS patients. Moreover, IL-33 was significantly higher in active AS patients according to Bath Ankylosing Spondylitis Disease Activity Index. IL-33 concentrations in serum were positively correlated with TNF-α and IL-17 levels (IL-33 and TNF-α, r = 0.54, P < 0.01; IL-33 and IL-17, r = 0.47, P < 0.01). IL-33 dose-dependently enhanced TNF-α and IL-6 productions by peripheral blood mononuclear cells (PBMCs) responding to lipopolysaccharide. IL-33 induced neutrophil migration only in higher doses (≥10 ng/ml). Serum levels of IL-33 were elevated in AS patients. IL-33 may play a role in AS development via enhancing TNF-α production by PBMCs and inducing neutrophil migration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.